FOR IMMEDIATE RELEASE
BioStratum Cofounder and Research Consortium Receive $16 Million Diabetes Research Grant From Novo Nordisk Foundation
Research Triangle Park, N.C., April 1, 1999 --
Dr. Tryggvason is heading a team of leading researchers from four Scandinavian
universities, including the Karolinska Institute in Stockholm, where he
is professor of medical chemistry and a Nobel Prize committee member.
The project is funded by a $16 million unrestricted grant from the Novo
Nordisk Foundation of Copenhagen and was presented to Dr. Tryggvason by
the Queen of Denmark
The research group will study both diabetes patients and people without the disease to determine the role of small blood vessels in causing damage to the kidneys and eyes. Previous research indicates that the damage may be caused by fundamental problems in the smallest vessels.
Diabetic complications are an enormous medical problem. Diabetes is the
leading cause of kidney failure and the leading cause of blindness. In
addition, the incidence
Dr. Tryggvason suggests that kidney damage may be impeded or even prevented
from occurring in the future.
During the last 10 years Dr. Tryggvason and other BioStratum investigators
have concentrated their research on the basal lamina, a thin membrane
present in nearly
“Our investment in Dr. Tryggvason's research is reaping significant rewards,” said Dr. Wesley Fox, Executive Vice President and cofounder of BioStratum. “Karl has already made a number of major contributions to understanding how the glomerulus functions in filtering blood, such as his recent discovery of the kidney filtration protein 'nephrin'.” These discoveries have identified novel therapeutic targets for important kidney diseases and BioStratum is pursuing development of treatments directed at these targets.
BioStratum is a privately held company developing proprietary therapeutics
based on recent scientific advances in basal lamina and related technologies.
The company's drug candidates are directed against novel